Arialys Therapeutics, Inc. — Form D
Arialys Therapeutics, Inc. of LA JOLLA, CA, a company, filed a Form D exempt-offering notice with the SEC on 2025-07-01. The offering totals $24.8M, of which $14.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-07-01
- Form: D
- Accession: 0002060132-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $24.8M
- Amount sold: $14.8M
- Remaining: $10.0M
- Investors: 7
- Date of first sale: 2025-06-13
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-550394
Issuer
- Name: Arialys Therapeutics, Inc.
- CIK: 0001956823
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 11099 NORTH TORREY PINES ROAD, SUITE 290, LA JOLLA, CA, 92037
- Phone: 858-750-4700
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Peter Flynn, Ph.D. | Director | San Diego, CA |
| Ed Hurwitz | Director | San Diego, CA |
| Jay Lichter, Ph.D. | Director | La Jolla, CA |
| Brian Slingsby, M.D., Ph.D., M.P.H. | Director | La Jolla, CA |
| Ashish Xavier, Ph.D. | Director | San Diego, CA |
| Peter Flynn, Ph.D. | Executive Officer | San Diego, CA |
| Tighe Reardon | Executive Officer | La Jolla, CA |
| Jay Lichter, Ph.D. | Executive Officer | La Jolla, CA |
Other filings by this issuer (1)
More